In a significant advancement for mental health treatment, the U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant major depressive disorder (MDD). This decision, announced on January 21, 2025, marks a pivotal shift in the management of depression, offering new hope […]